Both Semaglutide and this treatment represent new strategies to addressing blood sugar levels, and increasingly, obesity. Tirzepatide is a dual agonist that works on multiple receptors involved in glucose regulation: GLP-1 and GIP. This medication, often seen as a product name for Semaglutide, op